Serametrix, Ludwig Institute to Develop Cancer Rx-Response Test | GenomeWeb

NEW YORK (GenomeWeb News) — Personalized medicine company Serametrix announced today a partnership with the Ludwig Institute for Cancer Research to develop serum-based diagnostics to predict and monitor treatment response in cancer patients.

As part of the agreement, LICR has licensed to Serametrix tumor antigen patents surrounding the use of the antigen NY-ESO-1 as a predictor of drug response.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.